Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 720 B
EBIT 2018 -
Net income 2018 155 B
Debt 2018 716 B
Yield 2018 2,84%
Sales 2019 1 750 B
EBIT 2019 -
Net income 2019 140 B
Debt 2019 650 B
Yield 2019 2,84%
P/E ratio 2018 31,39
P/E ratio 2019 33,64
EV / Sales2018 3,33x
EV / Sales2019 3,24x
Capitalization 5 010 B
More Financials
Company
Takeda Pharmaceutical Co., Ltd. is a research-based global pharmaceutical company that engages in the manufacture, sale, import, export, and marketing of pharmaceutical drugs.It operates through the following segments: Ethical Drug, Consumer Healthcare, and Others.The Ethical Drugs segment includes... 
Sector
Pharmaceuticals
Calendar
11/01 | 07:00amEarnings Release
More about the company
Surperformance© ratings of Takeda Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on TAKEDA PHARMACEUTICAL CO L
10/20 TAKEDA PHARMACEUTICAL : and HemoShear partner to discover new treatments for liv..
10/19 TAKEDA PHARMACEUTICAL : Investigators at Takeda Pharmaceutical Company Report Fi..
10/19 TAKEDA PHARMACEUTICAL : Findings from Takeda Pharmaceutical Company Provides New..
10/19 TAKEDA PHARMACEUTICAL : New Findings from Takeda Pharmaceutical Company in the A..
10/19 TAKEDA PHARMACEUTICAL : and HemoShear Therapeutics Enter into Exclusive Drug Dis..
10/18 TAKEDA PHARMACEUTICAL : New Post Hoc Analyses Report Early Symptomatic Improveme..
10/17 TAKEDA PHARMACEUTICAL : and HemoShear Therapeutics Enter into Exclusive Drug Dis..
10/16 TAKEDA PHARMACEUTICAL : Presents Updated Results from Pivotal Phase 2 ALTA Trial..
10/13 TAKEDA PHARMACEUTICAL : Recursion Pharmaceuticals Announces Research Collaborati..
10/12 TAKEDA PHARMACEUTICAL : New Investigative Ophthalmology and Visual Science Study..
More news
Sector news : Pharmaceuticals - NEC
03:25a Recent hurricanes take toll on quarterly earnings
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
Latest Tweets
09/06CEO of Takeda Pharmaceutical prescribes stability after rough start
1
09/06#ovariancancer Takeda NoileImmune Sign CART Cell Therapy Deal: Takeda Pharmac.. 
09/06Takeda Pharmaceutical : Tries to Soothe Debt-Load Fears -- WSJ  
09/05Takeda Pharmaceutical prescribes stability after rough start
1
09/05We want to globalize our products and our company, Takeda Pharmaceutical CEO ..
3
More tweets
Qtime:34
News from SeekingAlpha
10/19 Prana Bio up 28% following research collaboration with Takeda
10/06 U.S. Orphan Drug tally
10/04 FDA OKs higher dose regimen of Takeda's cancer med Alunbrig; shares up 1%
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
10/03 Positive data from Takeda's late-stage study of uterine fibroid med relugolix..
Chart TAKEDA PHARMACEUTICAL CO L
Duration : Period :
Takeda Pharmaceutical Co L Technical Analysis Chart | 4502 | JP3463000004 | 4-Traders
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 6 444  JPY
Spread / Average Target 1,7%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
James Kehoe Director, Chief Financial & Corporate Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Shinji Ninomiya Manager-Research & Development
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD30.84%44 097
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214